Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
Joseph C MurrayLavanya SivapalanKarlijn HummelinkArchana BalanJames R WhiteNoushin NiknafsLamia RhymeeGavin PereiraNisha RaoBenny WekslerNathan BaharyJillian A PhallenAlessandro LealDavid L BartlettKristen A MarroneJarushka NaidooAkul GoelBenjamin LevySamuel RosnerChristine L HannSusan C ScottJosephine FelicianoVincent K LamDavid S EttingerQing Kay LiPeter B IlleiKim MonkhorstRobert B ScharpfJulie R BrahmerVictor E VelculescuBlair A JobePatrick M FordeValsamo AnagnostouPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Molecular responses assist with interpretation of heterogeneous clinical responses especially for patients with stable disease. Our complementary assessment of the peripheral tumor and immune compartments provides an approach for monitoring of clinical benefit and irAEs during immunotherapy.